Innovative non-clinical services.
We enable researchers across a variety of therapeutic areas to develop safer medicines.
Trusted by Senior Scientists & VPs
We assist pharmaceutical and biotechnology companies with ex vivo studies and deliver invaluable insights into how promising drug candidates effect complex biological systems in human blood.
With vast experience in immunology and laboratory practice, we perform the non-clinical studies based on our test system ID.Flow.
ID.Flow offers a unique approach to evaluating immunotoxicity in human whole blood. It also, holds the potential to study the mechanistic effects of drugs with the target in blood.
Our test site is certified according to GLP, and ID.Flow adheres to the 3Rs and New Approach Methodologies (NAMs) requirement.
Advanced therapies are increasingly being developed for patients in need, thereby putting pressure on drug developers to produce qualified, effective, and safe medicines. Immuneed combines our strong scientific knowledge with ID.Flow, a versatile ex-vivo system based on fresh, circulating human blood. Thereby, we provide our customers with a tailored solution in the early stage of development, enabling safe and effective drugs.
Background
The company was founded in 2014 and initially focused on the development of a novel immunotherapy for cancer. As the evaluation of this therapeutic vaccine grew more complex, we developed a proprietary platform to characterize the drug and predict outcomes in a clinical setting, thereby reducing animal studies and giving early indications of the effect in humans. In 2018, the vaccine project was acquired by Ultimovacs, a Norwegian pharmaceutical company. Today we are fully focused on developing Immuneed’s platform and associated services, which benefit biotech and pharmaceutical companies across the globe. By addressing important questions related to drug safety and immunology, we cut our customers’ costs and add value to drug development projects.
Feed
Category:Allpublicationsnewsinsights
No items available